Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced brea...

Full description

Saved in:
Bibliographic Details
Main Authors: The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, The Society of Onco‐Pathology of the China Anti‐Cancer Association
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Cancer Innovation
Subjects:
AKT inhibitor
breast cancer
expert consensus
hormone receptor
mTOR inhibitor
PI3K inhibitor
Online Access:https://doi.org/10.1002/cai2.70008
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cai2.70008

Similar Items